Inova launches next-gen EIA/IFA processor, 3/18
March 2018—Inova Diagnostics announced the launch of its Quanta-Lyser 3000, a fully automated enzyme-linked immunoassay and immunofluorescence assay processor for use in clinical laboratories.
Webinars and Sponsored Roundtables — Register Now
Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
cfDNA reference standard for EGFR mutations, 3/18
March 2018—Horizon Discovery launched its EGFR Multiplex cfDNA Reference Standard. The cell line-derived EGFR multiplex cell-free DNA reference standard allows laboratories and assay developers to optimize, validate, and routinely monitor performance of polymerase chain reaction–based tests, next-generation sequencing, and other novel assays designed to detect EGFR mutations from cfDNA.
Confocal laser scanning microscope, 3/18
March 2018—Olympus announced the availability of the FV3000 confocal laser scanning microscope in two upright models designed for in vitro and in vivo experiments.
Thermo Fisher unveils line of NGS instruments, 3/18
March 2018—Thermo Fisher Scientific announced the Ion GeneStudio S5 Series, a line of benchtop next-generation sequencing instruments that provides flexibility and scalability enabled by five Ion S5 chips, including the new Ion 550 chip, on a single platform. Research applications include cancer, inherited disease, and microbial and infectious diseases.
FDA-cleared Access AMH immunoassay, 3/18
March 2018—Beckman Coulter Diagnostics announced FDA clearance of its automated Access AMH immunoassay for in vitro diagnostic use. This test aids health care providers in the assessment of a woman’s ovarian reserve and helps guide the clinical management of women struggling with infertility or planning to become pregnant later in life.
Genoptix to acquire Rosetta Genomics, 3/18
March 2018—Genoptix and Rosetta Genomics announced they have entered into a definitive merger agreement under which Genoptix will acquire all of the outstanding shares of Rosetta Genomics for a total gross purchase price of $10 million.
Recombinant allergens, 3/18
March 2018—Meridian Life Science introduced its recombinant allergens for the development of serum-based IgE-mediated allergen diagnostic assays.
Updated CLSI Supplement M100, 3/18
March 2018—The Clinical and Laboratory Standards Institute published its annually updated antimicrobial susceptibility testing supplement, “M100: Performance Standards for Antimicrobial Susceptibility Testing, 28th ed.,” as well as its associated methodology standards, “M02: Performance Standards for Antimicrobial Disk Susceptibility Tests, 13th ed.” and “M07: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, 11th ed.” M100 is available packaged with either M02 or M07 or the three documents are available packaged together.
Ortho Vitros ALTV Slides, 3/18
March 2018—Ortho Clinical Diagnostics launched its Vitros ALTV Slides for the measurement of alanine aminotransferase, a key liver function enzyme found in serum and plasma, using dry slide technology.
Bordetella pertussis antigens for IVD use
March 2018—Binding Site’s Immunologicals Group has added three Bordetella pertussis (VZV) antigens to its offering of products for in vitro diagnostic manufacturing and research applications. The Bordetella pertussis FHA, Bordetella pertussis Toxin PT, and Bordetella pertussis Whole-Cell Antigens have been designed for use as integral components within solid phase enzyme immunoassay test procedures.